MRSN, US59045L2051

Mersana Therapeutics stock stood at USD 29.08 before its buyout

Published on 10/04/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mersana Therapeutics stock was last quoted at USD 29.08 on January 6, 2026. Day One completed a USD 173.0 million acquisition with USD 25.00 cash per share plus a CVR.

MRSN, US59045L2051, Illustration mit AI erstellt.

Mersana Therapeutics (ISIN US59045L2051) stock was last quoted at USD 29.08 on Nasdaq on January 6, 2026, at 4:00 p.m. ET, with a 0 percent change. The dated quote came as Day One Biopharmaceuticals completed its acquisition of Mersana, shifting the investment story from an independent biotech listing to a transaction built around cash consideration and contingent rights.

Buyout terms set the value

According to StockTitan, the transaction closed on January 6, 2026, after holders received USD 25.00 in cash for each Mersana share plus one non-tradable contingent value right. The CVR can pay up to an additional USD 30.25 per share if specified regulatory, commercial and net-sales milestones are achieved.

The same filing summary assigns the deal an estimated fair value of USD 173.0 million, comprising USD 125.0 million in cash and USD 48.0 million in contingent value rights. That structure makes the headline cash payment the certain component, while the CVR represents a separate claim tied to future development and commercial outcomes.

ADC pipeline drove the deal

StockTitan reports that the acquisition added Mersana's clinical-stage antibody-drug conjugate program emiltatug ledadotin, also known as Emi-Le, to Day One's pipeline. The transaction therefore centered on a drug-development asset rather than recurring commercial revenue.

The filing summary also records 3,029,135 shares tendered by January 5, 2026, equal to 60.57 percent of Mersana's outstanding stock. The comparison between USD 25.00 in immediate cash and the possible USD 30.25 CVR payment highlights the deal's two-part payoff structure.

Last quoted market snapshot

Mersana Therapeutics stock was last quoted at USD 29.08 on Nasdaq on January 6, 2026, at 4:00 p.m. ET. The same dated snapshot showed a 52-week range of USD 5.21 to USD 30.39, volume of 624,025 shares and market capitalization of USD 145.4 million.